Age: 49.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: COVID-19, Feeling abnormal, Interchange of vaccine products, SARS-CoV-2 test
Clinical narrative: Took Paxlovid, was negative by antigen test on last day, was feeling recovered. 5 days later I'm positive again and feeling terrible; Took Paxlovid, was negative by antigen test on last day, was feeling recovered. 5 days later I'm positive again and feeling terrible; Received Moderna vaccine follwed by Johnson and Johnson; This spontaneous case was reported by an other health care professional and describes the occurrence of COVID-19 (Took Paxlovid, was negative by antigen test on last day, was feeling recovered. 5 days later I'm positive again and feeling terrible), FEELING ABNORMAL (Took Paxlovid, was negative by antigen test on last day, was feeling recovered. 5 days later I'm positive again and feeling terrible) and INTERCHANGE OF VACCINE PRODUCTS (Received Moderna vaccine follwed by Johnson and Johnson ) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 vaccination.    Previously administered products included for Product used for unknown indication: Vyvanse on 01-Oct-2020. Past adverse reactions to the above products included No adverse event with Vyvanse. Concurrent medical conditions included Multiple sclerosis and Sulfonamide allergy (Sulfa drugs). Concomitant products included OCRELIZUMAB (OCREVUS) from 30-Apr-2022 to 30-Apr-2022 for an unknown indication.   On 01-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On 01-Mar-2022, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Received Moderna vaccine follwed by Johnson and Johnson ). On 14-May-2022 at 10:00 PM, the patient experienced COVID-19 (Took Paxlovid, was negative by antigen test on last day, was feeling recovered. 5 days later I'm positive again and feeling terrible) and FEELING ABNORMAL (Took Paxlovid, was negative by antigen test on last day, was feeling recovered. 5 days later I'm positive again and feeling terrible). At the time of the report, COVID-19 (Took Paxlovid, was negative by antigen test on last day, was feeling recovered. 5 days later I'm positive again and feeling terrible) and FEELING ABNORMAL (Took Paxlovid, was negative by antigen test on last day, was feeling recovered. 5 days later I'm positive again and feeling terrible) had not resolved and INTERCHANGE OF VACCINE PRODUCTS (Received Moderna vaccine follwed by Johnson and Johnson ) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2022, SARS-CoV-2 test: negative (Negative) was negative by antigen test and positive (Positive) 5 days later positive again.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   On 01-Mar-2022, patient received drug Johnson and Johnson in the left arm for unknown indication. No treatment medications were reported. Device Date was 16May2022 COMPANY COMMENT: This is an spontaneous case concerning a  49-years-old female patient with  medical history of Vyvanse on 01-Oct-2020 with No adverse event, OCRELIZUMAB on 30-Apr-2022, NIRMATRELVIR and RITONAVIR for COVID-19 vaccination, Concurrent medical conditions included Multiple sclerosis and Sulfonamide allergy and Johnson and Johnson COVID-19 vaccine before the events,   who experienced the unexpected events   of COVID-19 (AESI) and   FEELING ABNORMAL 226 days after  receiving the  1st  dose of  mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: COMPANY COMMENT: This is an spontaneous case concerning a  49-years-old female patient with  medical history of Vyvanse on 01-Oct-2020 with No adverse event, OCRELIZUMAB on 30-Apr-2022, NIRMATRELVIR and RITONAVIR for COVID-19 vaccination, Concurrent medical conditions included Multiple sclerosis and Sulfonamide allergy and Johnson and Johnson COVID-19 vaccine before the events,   who experienced the unexpected events   of COVID-19 (AESI) and   FEELING ABNORMAL 226 days after  receiving the  1st  dose of  mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.